Difference between revisions of "Selpercatinib (Retevmo)"
Jump to navigation
Jump to search
m |
|||
| Line 8: | Line 8: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *5/8/2020: Granted accelerated approval for | + | ===[[Non-small cell lung cancer]]=== |
| − | + | *5/8/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive [[Non-small cell lung cancer|non-small cell lung cancer (NSCLC)]] | |
| − | * | + | ===[[Thyroid cancer]]=== |
| − | * | + | *5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary [[thyroid cancer]] (MTC) who require systemic therapy |
| + | *5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive [[thyroid cancer]] who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). | ||
==Also known as== | ==Also known as== | ||
Revision as of 00:45, 30 November 2020
Mechanism of action
From the [NCI Drug Dictionary]: An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, LOXO-292 selectively binds to and targets various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity.
Diseases for which it is used
- RET-positive NSCLC
- RET-mutant medullary thyroid cancer
- RET-positive thyroid cancer
History of changes in FDA indication
Non-small cell lung cancer
- 5/8/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
Thyroid cancer
- 5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy
- 5/8/2020: Granted accelerated approval for adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Also known as
- Code name: LOXO-292
- Brand name: Retevmo